Antigen-specific therapies for the treatment of multiple sclerosis: a clinical trial update

Bibliography

• SPACK EG: Drugs in development for the treatment of multiple sclerosis: antigen-specific therapies. Exp. Opin. Invest. Drugs (1996) 5:1331–1348.
   Google Scholar
• WHITACRE CC, GIENAPP IE, MEYER A, COX KL, JAVED N: Treatment of autoimmune disease by oral tolerance to autoantigens. Gun. Immunol. Immunopathol. (1996) 80:S31–S39.
   PubMedGoogle Scholar
• WEINER HL: Oral tolerance for the treatment of autoim-mune diseases. Ann. Rev. Med. (1997) 48:341–351.
   PubMed Web of Science ®Google Scholar
• WEINER HL: Oral tolerance: immune mechanisms andtreatment of autoimmune diseases. Immunol Today (1997) 19:335–343.
   Google Scholar
• ZHANG J, STINISSEN P, MEDAER R, RAUS J: T cell vaccina-tion: clinical application in autoimmune diseases. J. Mol Med. (1996) 74:653–662.
   PubMed Web of Science ®Google Scholar
• STINISSEN P, ZHANG J, MEDAER R et al.: Vaccination with autoreactive T cell clones in multiple sclerosis: over-view of immunological and clinical data. J. Neurosci. Res. (1996) 45:500–511.
   PubMed Web of Science ®Google Scholar
• VANDENBARK AA, HASHIM GA, OFFNER H: T cell recep-tor peptides in treatment of autoimmune disease: ra-tionale and potential. J. Neurosci. Res. (1996) 43:391–402.
   PubMed Web of Science ®Google Scholar
• JOHNSON KP: A review of the clinical efficacy profile ofco-polymer 1: new US Phase III trial data. J. Neurol (1996) 243:S3–S7.
   PubMed Web of Science ®Google Scholar
• •References [2-8] provide recent reviews of specific ap-proaches to the treatment of autoimmunity that are currently applied to MS.
   Google Scholar
• MARTIN R, MCFARLAND H: Experimental immunothera-pies for multiple sclerosis. Springer Semin. Immunopa-thol. (1996) 18:1–24.
   PubMed Web of Science ®Google Scholar
• STINISSEN P, RAUS J, ZHANG J: Autoimmune pathogene-sis of multiple sclerosis: role of autoreactive T lympho-cytes and new immunotherapeutic strategies. Crit. Rev. Immunol. (1997) 17:33–75.
   PubMed Web of Science ®Google Scholar
• HOHLFELD R: Biotechnological agents for the immuno-therapy of multiple sclerosis: principles, problems and perspectives. Brain (1997) 120:865–916.
   PubMed Web of Science ®Google Scholar
• NOSEWORTHY JH, MILLER DH: Measurement of treatment efficacy and new trial results in multiple sclero-sis. Curr. Opin. Neurol (1997) 10:201–210.
   PubMed Web of Science ®Google Scholar
• •References [9-12] provide excellent recent reviews of the re-search and clinical trial designs supporting antigen-specific MS therapies.
   Google Scholar
• ROCKEN M, RACKE M, SHEVACH EM: IL-4 induced im-mune deviation as antigen-specific therapy for inflam-matory autoimmune disease. Immunol Today (1996) 17:225–231.
   PubMedGoogle Scholar
• •A good review of the data supporting the model of immune deviation and the clinical implications of this paradigm.
   Google Scholar
• SHARIEF MK, HENTGES R: Association between tumornecrosis factor-a and disease progression in chronic progressive multiple sclerosis. New Engl. J. Med. (1991) 325:467–472.
   PubMed Web of Science ®Google Scholar
• CANNELLA B, RAINE CS: The adhesion molecule and cy-tokine profile of multiple sclerosis lesions. Ann. Neurol. (1995) 37:424–435.
   PubMed Web of Science ®Google Scholar
• PANITCH HS, HIRSCH RL, SCHINDLER J, JOHNSON KP:Treatment of multiple sclerosis with gamma inter-feron: exacerbations associated with activation of the immune system. Neurology (1987) 37:1097–1102.
   PubMed Web of Science ®Google Scholar
• LEONARD JP, WALDBURGER KE, GOLDMAN SJ: Preven-tion of experimental autoimmune encephalomyelitis by antibodies against interleukin 12. J. Exp. Med. (1995) 181:381–386.
   PubMed Web of Science ®Google Scholar
• RACKE MK, BONOMO A, SCOTT DE et al.: Cytokine-induced immune deviation as a therapy for inflamma-tory autoimmune disease. J. Exp. Med. (1994) 180:1961–1966.
   PubMed Web of Science ®Google Scholar
• MATUSEVICIUS D, NAVIKAS V, SODERSTROM M et al:Multiple sclerosis: the proinflammatory cytokines lym-photoxin-a and tumour necrosis factor-a are upregu-lated in cerebrospinal fluid mononuclear cells. J. Neuroimmunol. (1996) 66:115–123.
   PubMed Web of Science ®Google Scholar
• DRULOVIC J, MOSTARICA-STOJKOVIC M, LEVI Z et al.:Interleukin-12 and tumor necrosis factor-a levels in cerebrospinal fluid of multiple sclerosis patients. J. Neurol. Sci. (1997) B147:145–150.
   Google Scholar
• SHAW MK, LORENS JB, DHAWAN A et al.: Local delivery ofinterleukin 4 by retrovirus-transduced T lymphocytes ameliorates experimental autoimmune encephalo-myelitis. J. Exp. Med. (1997) 85:1711–1714.
   Google Scholar
• HEMMER B, VERGELLI M, CALABRESI P et al.: Cytokine phenotype of human autoreactive Tee! clones specific for the immunodominant myelin basic protein peptide (83-99). J. Neurosci. Res. (1996) 45:852–862.
   PubMed Web of Science ®Google Scholar
• LAFAILLE JJ, VAN DE KEERE F, HSU AL et al: Myelin basic protein-specific T helper 2 (Th2) cells cause experi-mental autoimmune encephalomyelitis in immunode-ficient hosts rather than protect them from disease. J. Exp. Med. (1997) 186:307–312.
   PubMed Web of Science ®Google Scholar
• •References [22,23] show the complexities of interpreting the role of Thl/Th2 cytokine balance in MS and EAE.
   Google Scholar
• STEINMAN L: Some misconceptions about understand-ing autoimmunity through experiments with knock-outs. J. Exp. Med. (1997) 185:2039–241.
   PubMed Web of Science ®Google Scholar
• GENAIN CP, ABEL K, BELMAR N et al.: Late complications of immune deviation therapy in a nonhuman primate. Science (1997) 274:2054–2057.
   Web of Science ®Google Scholar
• A study in the marmoset model of EAE with important impli-cations for immune deviation-based therapies.
   Google Scholar
• GENAIN CP, HAUSER SL: Creation of a model for multiple sclerosis in Callithrix jacchus marmosets. J. Mol. Med. (1997) 75:187–197.
   PubMed Web of Science ®Google Scholar
• MCFARLAND H: Complexity in the treatment of autoimmune disease. Science (1997) 274:2037–2038.
   Web of Science ®Google Scholar
• ZHANG J, VANDEVYVER C, STINISSEN P, RAUS J: In vivo clonotypic regulation of human myelin basic protein-reactive T-cells by T-cell vaccination. J. Immunol. (1995) 155:5868–5877.
   PubMed Web of Science ®Google Scholar
• MEDAER R, STINISSSEN P, TRUYEN L, RAUS J, ZHANG J: Depletion of myelin-basic-protein autoreactive T-cells by T-cell vaccination: pilot trial in multiple sclerosis. Lancet (1995) 346:807–808.
   PubMed Web of Science ®Google Scholar
• WILSON DB, GOLDING AB, SMITH RA et al: Results of a Phase I clinical trial of a T-cell receptor peptide vaccine in patients with multiple sclerosis. I. Analysis of T-cell receptor utilization in CSF cell populations. J. Neuroim-munol (1997) 76:15–28.
   Google Scholar
• GOLD DP, SMITH RA, GOLDING AB et al.: Results of a Phase I clinical trial of a T-cell receptor peptide vaccine in patients with multiple sclerosis. II. Comparative analysis of TCR utilization in CSF T-cell populations be-fore and after vaccination with a TCRVI36 CDR2 peptide. J. Neuroimmunol. (1997) 76:29–38.
   Google Scholar
• References [30,31] detail the rationale and Phase I results ofThe Immune Response Corporation's IR208, a TCR V136-derived peptide vaccine.
   Google Scholar
• VANDENBARK AA, HASHIM G, OFFNER H: Immunization with a synthetic T-cell receptor V region peptide pro-tects against EAE. Nature (1989) 341:541–544.
   PubMed Web of Science ®Google Scholar
• BROSTOFF SW: Vaccination with T-cell receptor pep-tides. In: Monoclonal Antibodies and Peptide Therapy in Autoimmune Diseases. J-F Bach (Ed.), Marcel Dekker, Inc., (1993):203–218.
   Google Scholar
• THE IMMUNE RESPONSE CORP.: The Immune Response Corporation announces results from Phase II clinical trials for rheumatoid arthritis and psoriasis. Press Re-lease (7 January 1997)
   Google Scholar
• BOURDETTE DN, WHITHAM RH, CHOU YK et al.: Immu-nity to TCR peptides in multiple sclerosis. I. Successful immunization of patients with synthetic V135.2 and VI36.1 CDR2 peptides. J. Immunol (1994) 152:2510–2519.
   Google Scholar
• CHOU YK, MORRISON WJ, WEINBERG AD et al.: Immu-nity to TCR peptides in multiple sclerosis. II. T-cell rec-ognition of V65.2 and V66.1 CDR2 peptides. J. Immunol. (1994) 152:2520–2529.
   Google Scholar
• VANDENBARK AA, CHOU YK, WHITHAM R et al.: Treat-ment of multiple sclerosis with T-cell receptor pep-tides: results of a double-blind pilot trial. Nature Med. (1996) 2:1109–1115.
   PubMed Web of Science ®Google Scholar
• Phase I trial results of Connetics' TCR peptide vaccine.
   Google Scholar
• ALLEGRETTA M. Regulation of MS and EAE with T cell re-ceptor (TCR) peptides. IBC Fifth Annual Conference on Multiple Sclerosis, Cambridge, MA, 16–17, June (1997).
   Google Scholar
• WEINER HL: Mechanisms of oral tolerance. IBC Fifth An-nual Conference on Multiple Sclerosis. Cambridge, MA,16–17, June (1997).
   Google Scholar
• MILLER A, LIDER O, ROBERTS AB, SPORN M, WEINER HL:Suppressor T-cells generated by oral tolerance to mye-lin basic protein suppress both in vitro and in vivo im-mune responses by the release of TGF-I3 following antigen specific triggering. Proc. Natl. Acad. Sci. USA (1992) 89:421–425.
   PubMed Web of Science ®Google Scholar
• FUKAURA H, KENT SC, PIETRUSEWICZ MJ et al.: Inductionof circulating myelin basic protein and proteolipid protein-specific transforming growth factor-131-secreting Th3 T-cells by oral administration of myelin in multiple sclerosis patients. J. Clin. Invest. (1996) 98:70–77.
   PubMed Web of Science ®Google Scholar
• WEINER HL, MACKIN GA, MATSUI M et al.: Double-blindpilot trial of oral tolerization with myelin antigens in multiple sclerosis. Science (1993) 259:1321–1324.
   PubMed Web of Science ®Google Scholar
• FLETCHER M: Phase III trial of Myoral. IBC Fifth AnnualConference on Multiple Sclerosis. Cambridge, MA, 16–17, June (1997).
   Google Scholar
• AUTOIMMUNE, INC.: AutoImmune announces results from Phase III clinical trial of myoral® for multiple scle-rosis. Press Release. (21 April 1997).
   Google Scholar
• AUTOIMMUNE, INC AutoImmune announces preliminary results from two Phase II clinical trials of colloral for rheumatoid arthritis. May 12 (1997) (Press Release)
   Google Scholar
• NUSSENBLATT RB, GERY I, WEINER HL et al.: Treatment ofuveitis by oral administration of retinal antigens: re-sults of a Phase I/II randomized masked trial. Am. J. Ophthalmol. (1997) 123:583–592.
   PubMed Web of Science ®Google Scholar
• ELLIOTT EA, MCFARLAND HI, NYE SH et al.: Treatment ofexperimental encephalomyelitis with a novel chimeric fusion protein of myelin basic protein and proteolipid protein. J. Clin. Invest. (1996) 98:1602–1612
   PubMed Web of Science ®Google Scholar
• CRITCHFIELD JM, RACKE MK, ZUNIGA-PFLUCKER JC et al:T cell deletion in high antigen dose therapy of autoim-mune encephalomyelitis. Science (1994) 263:1139–1143.
   PubMed Web of Science ®Google Scholar
• ALEXION PHARMACEUTICALS: New drug may be effec-tive treatment for MS. April 28 (1997). (Press Release).
   Google Scholar
• WARREN KG et al.: Anti-myelin basic protein and anti-proteolipid protein specific forms of multiple sclero-sis. Ann. Neurol. (1994) 35:280–289.
   PubMed Web of Science ®Google Scholar
• WARREN KG, CATZ I: Diagnostic value of cerebrospinalfluid anti-myelin basic protein in patients with multi-ple sclerosis. Ann. Neurol (1986) 20:20–25.
   PubMed Web of Science ®Google Scholar
• WARREN KG, CATZ I: Cerebrospinal fluid autoantibod-ies to myelin basic protein in multiple sclerosis. Detec-tion during first exacerbation and kinetics of acute relapses and subsequent convalescent phases. J. Neurol. ScL (1989) 91:143–151.
   Google Scholar
• WARREN KG, CATZ I, STEINMAN L: Fine specificity of theantibody response to myelin basic protein in the cen-tral nervous system in multiple sclerosis: the minimal B cell epitope and a model of it features. Proc. Natl. Acad. Sci. USA (1995) 82:11061–11065.
   Google Scholar
• •Proximity of the major T- and B-cell epitopes of MBP may have important consequences in disease and treatment.
   Google Scholar
• WARREN KG, CATZ I: Administration of myelin basicprotein synthetic peptides to multiple sclerosis pa-tients. J. Neurol ScL (1995) 133:85–94.
   PubMed Web of Science ®Google Scholar
• WARREN KG, CATZ I: The effect of intrathecal MBP syn-thetic peptides containing epitope P85VVHFFK NOVTP96 on free anti-MBP levels in acute relapsing multiple sclerosis. J. Neurol Sci. (1997) 148:67–78.
   PubMed Web of Science ®Google Scholar
• BOND AP, CORLETT L, SPACK E et al: Diverse patterns ofunresponsiveness induced by TCR engagement with-out costimulation. New York Academy of Sciences Confer-ence. Santa Monica, CA, 7–10, May (1997).
   Google Scholar
• MCCUTCHEON M, WEHNER N, WENSKY A et al.: A sensi-tive ELISPOT assay to detect low-frequency human T lymphocytes. J. Immunol. Methods (1997). (In Press).
   Google Scholar
• SPACK EG: Monitoring MS patient T cell reactivity be-fore and during clinical trial with a modified ELISPOT assay. IBC Fifth Annual Conference on Multiple Sclerosis. Cambridge, MA,16–17, June (1997).
   Google Scholar
• SPACK EG, MCCUTCHEON M, HSIAO L eta].: Prevalence of T cell reactivity to myelin basic protein (MBP) peptide 84–102 in HLA-DR2+ and HLA-DR2-multiple sclerosis (MS) patients. ASMB/ASIP/AAI Meeting New Orleans, LA, 2–6, June (1996)
   Google Scholar
• DEVAUX B, ENDERLIN F, WALLNER B, SMILEK DE: Induc-tion of EAE in mice with recombinant human MOG, and treatment of EAE with a MOG peptide. J. Neuroimmunol. (1997) 75:169–173.
   PubMed Web of Science ®Google Scholar
• SAMSON MF, SMILEK DE: Reversal of acute experimentalautoimmune encephalomyelitis and prevention of re-lapses by treatment with a myelin basic protein peptide analogue modified to form long-lived peptide-MHC complexes. J. Immunol (1995) 155:2737–2746.
   PubMed Web of Science ®Google Scholar
• HAPP MP: Peptide vaccines for the treatment of multiplesclerosis. In: Vaccines II: New Advances in Technologies and Applications, International Business Communications, Inc., Library Series, Southborough, MA (1997)241–266.
   Google Scholar
• VALLI A, SETTE A, KAPPOS L et al.: Binding of myelin ba-sic protein peptides to human histocompatibility leu-kocyte antigen class II molecules and their recognition by T-cells from multiple sclerosis patients. J. Clin. Invest. (1993) 91:616–628.
   PubMed Web of Science ®Google Scholar
• EVAVOLD BD, ALLEN PM: Separation of IL-4 productionfrom Th cell proliferation by an altered T-cell receptor ligand. Science (1991) 252:1308–1310.
   PubMed Web of Science ®Google Scholar
• •A key paper in the early characterisation of altered peptide ligands.
   Google Scholar
• GAUR A, BOEHME SA, CHALMERS D et al.: Amelioration of relapsing experimental autoimmune encephalomyeli-tis with altered myelin basic protein peptides involves different cellular mechanisms. J. Neuroimmunol. (1997) 74:149–158.
   PubMed Web of Science ®Google Scholar
• VERGELLI M, HEMMER B, UTZ U et al.: Differential activa-tion of human autoreactive T cell clones by altered pep-tide ligands derived from myelin basic protein (87-99). Eur. j Immunol. (1996) 26:2624–2634.
   PubMed Web of Science ®Google Scholar
• KARIN N, MITCHELL DJ, BROCKE S, LING N, STEINMAN L: Reversal of experimental autoimmune encephalomye-litis by a soluble peptide variant of a myelin basic pro-tein epitope: T-cell receptor antagonism and reduction of interferon gamma and tumor necrosis factor alpha production. J. Exp. Med. (1994) 180:2227–2237.
   PubMed Web of Science ®Google Scholar
• WINDHAGEN A, SCHOLZ C, HOLLSBERG P et al.: Modula-tion of cytokine patterns of human autoreactive T-cell clones by a single amino acid substitution of their pep-tide ligand. Immunity (1995) 2:373–380.
   PubMed Web of Science ®Google Scholar
• BORNSTEIN MB, MILLER A, SLAGLE S eta].: A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis. New Engl. I. Med. (1987) 317:408–414.
   Google Scholar
• BORNSTEIN MB, MILLER A, SLAGLE S et al.: A placebo-controlled, double-blind, randomized, two-center, pi-lot trial of Cop 1 in chronic progressive multiple sclero-sis. Neurology (1991) 410:533–539.
   Google Scholar
• JOHNSON KP, BROOKS BR, COHEN JA et al.: Co-polymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a Phase III multicenter, double-blind, placebo-controlled trial. Neurology (1995) 45:1268–1276.
   PubMed Web of Science ®Google Scholar
• •The key clinical trial report on Copaxone.
   Google Scholar
• JOHNSON KP, BROOKS BR, COHEN JA et al.: Extended use of co-polymer 1 maintains clinical effect on multiple sclerosis relapse rate and degree of disability. Neurol-ogy. (In Press).
   Google Scholar
• MANCARDI GL, SARDANELLI F, PARODI RC et al.: The ef-fect of co-polymer-1 on serial gadolinium enhanced magnetic resonance scans in relapsing remitting multi-ples sclerosis [Abstract]. Eur. j Neurol. (1996) 3 (Suppl. 4):33.
   Google Scholar
• KORCZYN AD, NISIPEANU P: Safety profile of co-polymer-1: analysis of cumulative experience in the United States and Israel. J. Neurol (1996) 243 (Suppl. 1):S23–S26.
   Google Scholar
• •J. Neurol. 243 (Suppl. 1) is devoted to reviews of Copaxone development and clinical trials.
   Google Scholar
• JOHNSON KP, TEITELBAUM D, ARNON R: Antibodies to co-polymer 1 do not interfere with its clinical effect. Ann. Neurol (1995) 38:973.
   Google Scholar